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Abstract Nanomaterials and their associated tech-
nologies hold promising opportunities for the
development of new materials and applications in a
wide variety of disciplines, including medicine,
environmental remediation, waste treatment, and
energy conservation. However, current information
regarding the environmental effects and health risks
associated with nanomaterials is limited and
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DOI 10.1007/s11051-008-9514-9sometimes contradictory. This article summarizes the
conclusions of a 2008 NATO workshop designed to
evaluate the wide-scale implications (e.g., beneﬁts,
risks, and costs) of the use of nanomaterials on
human health and the environment. A unique feature
of this workshop was its interdisciplinary nature and
focus on the practical needs of policy decision
makers. Workshop presentations and discussion pan-
els were structured along four main themes:
technology and beneﬁts, human health risk, environ-
mental risk, and policy implications. Four
corresponding working groups (WGs) were formed
to develop detailed summaries of the state-of-the-
science in their respective areas and to discuss
emerging gaps and research needs. The WGs iden-
tiﬁed gaps between the rapid advances in the types
and applications of nanomaterials and the slower
pace of human health and environmental risk science,
along with strategies to reduce the uncertainties
associated with calculating these risks.
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Introduction
Many potential questions are associated with the
current state of development and use of nanomate-
rials. For example, with the availability of over 600
consumer products worldwide claiming to contain
nanomaterials, what information exists that identiﬁes
their risk to human health and the environment? What
engineering and other personal and environmental
protection controls can be deployed to minimize the
potential human and environmental health and safety
impacts of nanomaterials throughout the manufactur-
ing and product lifecycles? How can the potential
environmental and health beneﬁts of nanotechnology
be realized? To discuss and develop expert answers to
questions, such as these, the NATO Advanced
Research Workshop ‘‘Nanomaterials: Environmental
Risks and Beneﬁts and Emerging Consumer Prod-
ucts’’ brought together 70 scientists and engineers
from 19 different nations and multiple ﬁelds, reﬂect-
ing the global and interdisciplinary nature of
nanotechnology and nanomaterials research. The
workshop had ﬁve primary purposes:
• Describe the potential beneﬁts of nanotechno-
logy-utilizing commercial products.
• Identify and describe what is known about the
environmental and human health risks of nano-
materials and the approaches to assess their safety.
• Assess the suitability of multicriteria decision
analysis for reconciling the beneﬁts and risks of
nanomaterials and nanotechnology.
• Provide direction for future research in nanotech-
nology and environmental science to address
issues associated with emerging nanomaterial-
containing consumer products.
• Identify strategies for users in developing coun-
tries to best manage this rapidly developing
technology and its associated risks, and to realize
its beneﬁts.
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123State-of-the-science reviews of nanotechnology
were presented during the plenary sessions by
renowned experts in the ﬁeld, and over 20 poster
presentations provided insights regarding speciﬁc
projects and issues of interest to the nanotechnology
community. Discussion panels were held to debate
the implications of this information and to begin
clarifying gaps in current knowledge and four
working groups (WGs) were formed to detail these
gaps and propose solutions to address them. The WGs
discussed methods and applications speciﬁc to the
following areas: (i) technology and beneﬁts, (ii)
human health risks, (iii) environmental risks, and (iv)
policy implications. Prior to the conference, WG
chairs prepared and circulated topical white papers,
providing a starting point for the detailed WG
discussions during the meeting. This summary paper
was initially drafted by the workshop organizers and
WG chairs and rapporteurs during a one-day meeting
immediately following the workshop. The conclu-
sions described for each WG are based on
a prioritized list agreed upon during the post-work-
shop session. These efforts highlight the signiﬁcant
challenges to professionals in assessing the risks
associated with nanotechnology; such assessments
will almost certainly require a highly integrative and
adaptive process of decision-making for nanomaterial
risk assessment. The full reports from each WG are
published in Linkov and Steevens (2009), but the
concepts discussed and conclusions made are sum-
marized in the following pages.
Nanotechnology, its applications, consumer
products, and beneﬁts
State of the ﬁeld
Nanotechnologies already provide new exciting
applications in materials science, communications,
electronics, medicine, energy, and the environment,
to name just a few areas. Nanotechnology represents
a platform technology that utilizes the properties of
matter that arise at the nanometer scale. Many
nanomaterials are currently being produced (some
have been for many years), such as carbon black,
fumed silica, carbon nanotubes, fullerenes, silver
nanoparticles, polymer nanocomposites, dendrimers,
metal oxides, organic and inorganic semiconductors,
and nanocatalysts. Nanomaterials are used, for
example, in coatings, emulsions, dispersions and
ﬁlms in automobile components, paper, cosmetics,
textiles, and electronic displays. The unique physi-
cochemical characteristics of nanomaterials,
particularly the high surface-to-volume ratio (inﬂu-
encing solubility, chemical reactivity, and catalytic
activity) and quantum effects (inﬂuencing colour,
magnetism, hardness, and electronic properties),
make them important drivers of innovation with the
potential to beneﬁt the world’s entire population.
Nanotechnology can thus be viewed as a cross-
sectional and enabling technology.
Nanomedicine
The application of nanotechnology in health care,
termed nanomedicine, offers new opportunities to
signiﬁcantly improve medical diagnosis and treat-
ment of diseases, such as cardiovascular disease,
cancer, diabetes, musculoskeletal disorders, and neu-
rodegenerative diseases (European Technology
Platform 2006). The main areas of activity are
nanotechnology-based diagnostics and imaging, tar-
geted delivery of multi-tasking medicines, and
regenerative medicine. In vivo diagnostic technology
is based on nanoparticle contrast agents, particularly
for MRI and ultrasound. In vitro diagnostic techno-
logy attempts to develop novel sensor concepts that
are based on nanotubes, nanowires, cantilevers, or
atomic force microscopy, with an aim to improve
sensitivity, reduce production costs, or measure novel
analytes. Development of multifunctional nanocarriers
associated with drugs and possessing targeting capa-
bilities offers new opportunities for cancer therapy.
Regenerative medicine employs novel cell culture
techniques combined with the design of biocompatible
polymers, enabling advanced therapeutic tissue engi-
neering (European Technology Platform 2006).
Environment
Environmental nanotechnology applications can be
divided into two groups: (1) environmental techno-
logy applications that will reduce pollution, and (2)
technologies that will remediate pollutants that accu-
mulate in the environment. The ﬁrst category consists
of environmentally beneﬁcial approaches, such as
J Nanopart Res (2009) 11:513–527 515
123green design, green chemistry, and green manufac-
turing. The second category includes a group of
different nanomaterials that, due to their chemical
reactivity and high surface area, are being applied to
soil and water for decontamination. For example, iron
nanopowders are already in use for effective detoxi-
ﬁcation of soils for a variety of organic contaminants.
Nanotechnology also offers the potential of novel
materials for treatment of surface water, groundwater,
and wastewater contaminated by toxic metal ions,
organic and inorganic contaminants, and pathogenic
microorganisms. Due to their unique activities toward
recalcitrant contaminants, many nanomaterials are
under active research and development. Accordingly,
literature about current research on different nano-
materials (nanostructured catalytic membranes,
nanosorbents, nanocatalysts, and bioactive nanopar-
ticles) and their application in water treatment,
puriﬁcation, and disinfection has been recently
reviewed (Theron et al. 2008).
Energy
To meet the energy demands of a future world with a
larger population and a growing dependence on
power, technological breakthroughs that advance
energy conversion, storage, and savings are needed.
A report of the National Nanotechnology Initiative
(NNI 2004) identiﬁes a number of strategic research
targets in which nanotechnology is likely to have the
greatest impact by forming alternatives to fossil fuels.
These targets include:
• Hydrogen production from sunlight and water,
• Solar cells with 20% power efﬁciency and
100 times lower cost than current cells,
• Solid-state lighting requiring half the power
consumption of current technologies, and
• Super-strong, light-weight materials to improve
the fuel efﬁciency of the transportation sector.
The use of nanotechnology is expected to cut costs
both of solar cells and of the equipment needed to
deploy them, making solar power economical and
hence a more usable alternative to fossil fuels.
Nanotechnology may also contribute to reductions
in energy demand through lighter materials for
vehicles, materials and geometries that contribute to
more effective temperature control, technologies that
improve manufacturing process efﬁciency, materials
that increase the efﬁciency of electrical components
and transmission lines, and materials that could
contribute to a new generation of fuel cells and a
potential hydrogen economy.
Consumer products
As noted in the above sections, nanotechnology
heralds a world of better and more durable consumer
products. In 2006, nanotechnology was incorporated
into more than $50 billion worth of manufactured
goods. The Project on Emerging Nanotechnologies
(PEN) maintains an inventory of consumer products
that claim to utilize nanomaterials. As of May 15,
2008, this inventory contained 610 products or
product lines produced by 322 companies located in
20 countries. This online list of company-identiﬁed
nanotechnology consumer products includes mer-
chandise from such well-known brands as Samsung,
Black & Decker, Eddie Bauer, and others (PEN 2008)
Since this list relies on manufacturers self-identifying
products that may contain nanomaterials or use
nanotechnologies in the manufacturing process, it is
not an all-inclusive inventory. Other inventories are
maintained, for instance, in Japan, although language
differences may hinder their utilization (e.g., AIST
2008).
Beneﬁts and implications
Rapid advances in materials science and technology
that enable the manipulation of matter at the nano-
meter scale will continue to allow the realization of
many beneﬁts of nanotechnology. Foremost among
these will be a new manufacturing paradigm.
While techniques for manufacturing nanomaterials
are as varied as the materials themselves, they can be
divided into 2 main types of approaches: ‘‘bottom-up’’
and ‘‘top-down.’’ The building of structures atom-by-
atom or molecule-by-molecule forms the basis for
bottom-up manufacturing and can be split into three
categories: chemical synthesis, self-assembly, and
positional assembly (The Royal Society and Royal
Academy of Engineering UK 2004). Bottom-up
methods are widely used for manufacturing of metal
nanoparticles, nanoﬁlms, fullerenes, nanotubes, and
quantum dots. Top-down manufacturing, meanwhile,
involves starting with a micrometer- to millimeter-
sized piece of material and etching, milling, or
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material using precision engineering or lithography
techniques. Top-down manufacturing can be used for
creating computer chips, precision-engineered sur-
faces, and metal oxanes (Wiesner et al. 2006).
In addition to enabling a new manufacturing
paradigm, another beneﬁt of nanotechnology would
be its potential to help sustain the world’s resources.
At the workshop, this beneﬁt was discussed along
with the view of Petersen and Egan (2002), who
believe that nanotechnology is a technology which,
for the ﬁrst time in history, holds the promise of
providing inexpensive energy, food, and clean water
for everyone on the planet; it could thus be used also
in innovative ways to encourage political stability
and responsibility.
Economically, current projections put the global
market for nanotechnology and nanomaterial-con-
taining products at an estimated $2.6 trillion by 2014
(Lux Research 2004). A more recent forecast by
Business Communications Co. Research predicts the
market for nanomaterials, nanotools, and nanodevices
to be worth $12.7 billion by the end of this year.
While being more conservative than Lux Research,
this estimate calls for a doubling of the $12.7 billion
market value in the next 5 years (BCC Research
2008). It should be noted here that the public sector
leads the private sector in terms of investing in
nanotechnological advancements worldwide and that
the developed nations are the primary investors (Lux
Research 2004). Therefore, a very signiﬁcant chal-
lenge is ensuring an even distribution of beneﬁts
throughout the world community.
Ways to overcome problem
Given the large number of applications being
designed that utilize nanomaterials and nanotechno-
logies, and the perception that nanotechnology is, or
will be, a panacea for the world’s problems, questions
arise regarding who beneﬁts from these technological
advances. The popular press generally touts nano-
technology products as beneﬁcial to society, while
not necessarily distinguishing between the real and
potential beneﬁts of the technology. The Technology
and Beneﬁts WG acknowledged that the promise of
economic returns drives investments, which in turn
lead to technological advances. Taking three exam-
ples, one each from applications of nanotechnology
to medicine, the environment, and energy, we
evaluated the health risks, environmental risks, total
investment, health and environmental beneﬁts, return
on investment, and size of population impacted. The
estimates for these parameters were best estimates
based on information available from the NanoRoad-
Map (NRM) project of the EU 6th Framework. This
preliminary prediction showed that beneﬁts were
indeed not evenly distributed across the world. There
was also a clear recognition among all workshop
participants that resolving the question of who
beneﬁts from nanotechnology lies in pulling together
multidisciplinary expertise from multiple nations.
Issues of technical or economic capacity would have
to be addressed through collaboration not just across
disciplines but between the developed and developing
nations to level the playing ﬁeld. Just as market
pressures drive investment, it is hoped that ethical
and social imperatives would drive fair access to
beneﬁts of nanomaterials. Concurrent advances in
methods to protect human and environmental health
will have to lead the initiative on facilitating acces-
sibility so that asymmetric beneﬁts are not created.
Although interdisciplinary collaboration was not the
focus of this WG’s deliberations, it was brought up as
a subject addressed by the WG on policy. Finally, it
was observed that one of the strengths of nanotech-
nology is its cross-disciplinary approach. Simply put,
ideas and products originally developed for medical
and biological purposes ﬁnd applications in electron-
ics or energy industries. This has in turn pushed
scientists, medical doctors, and engineers to signif-
icantly revise and modify their approach to problem
solving to rapidly adopt new ideas and techniques.
The ultimate beneﬁciary of such a shift in thinking
will be humanity.
Human health risk and implications
State of the ﬁeld
There are several articles in the literature that review
current concepts of nanomaterial toxicology and risk
assessment (Balbus et al. 2007; Borm et al. 2006;
Holsapple et al. 2005; Nel et al. 2006; Oberdo ¨rster
et al. 2005; Stone et al. 2007). The purpose of the
Human Health WG was not to re-review the literature,
but to consider important ﬁndings in the context of a
J Nanopart Res (2009) 11:513–527 517
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assessment process. Participants discussed mecha-
nisms by which nanomaterials might pose a risk to
human health, including nanosized particles penetrat-
ing epithelial barriers at the portal of entry and
inducing oxidative stress. Both of these processes are
fundamentally tied to the physical and chemical
nature of the material itself. An important point is
that there is no such thing as a generic ‘‘nanomate-
rial,’’ as factors, such as size, shape, chemistry, and
solubility affects the biological interactions and
consequences of exposure to a speciﬁc nanoparticle.
This is highlighted by recent reports of impacts from
carbon nanotubes (Poland et al. 2008) and nano silver
(Benn and Westerhoff 2008). The goal that should be
kept in sight, similar to a recent commentary (Hansen
et al. 2008), is to facilitate actions taken by regulatory
bodies that are charged with protecting human and
environmental health through the reduction in uncer-
tainties and prioritization of health-based research.
It is neither feasible nor sensible to conduct safety
evaluations for all nanomaterials in current or future
production; therefore, a risk assessment paradigm
should be ﬂexible and based on current knowledge of
similar materials (Linkov et al. 2008). Along these
lines, people are regularly exposed to nanosized
particles in ambient air (i.e., ultraﬁne particles) that
are derived from combustion processes. Although
there are physicochemical differences between engi-
neered nanomaterials and ambient ultraﬁne particles,
the large body of toxicological literature regarding
the latter provides a framework for understanding
nanomaterial risks. In addition, large-volume pro-
duction of nanosized titanium dioxide and carbon
black particles has been carried out for several years,
and it is possible that aspects of the risk assessment
paradigms for these materials could be applied more
generally to nanomaterials. Useful predictive guid-
ance can also be gained from the literature regarding
interactions of nanosized particles with skin, focusing
on penetration of the stratum corneum and drug
delivery. Although this approach focuses mainly on
the respiratory tract and skin, such simpliﬁcation is
reasonable because of the ways in which humans are
likely to be exposed to nanomaterials, namely in
occupational and environmental settings and via
consumer products.
An area that is gaining considerable interest and
attention is the role of biomolecules, such as proteins
as mediators in the interactions of nanoparticles with
living systems (Cedervall et al. 2007a, b; Lynch et al.
2006, 2007). For example, apolipoprotein E has been
associated with transport to the brain, and recent
evidence has indicated that nanoparticles coated with
apolipoprotein E can reach the brain (Michaelis et al.
2006). Thus, one can begin to see how identiﬁcation
of proteins bound to nanoparticles could predict
uptake and distribution, target organs, and cellular
and tissue responses. Such predictive information
linked with mechanistic knowledge could signiﬁ-
cantly contribute to reductions in the uncertainties of
nanomaterials risk assessment.
Impediments to risk assessment
Several impediments to successful risk assessment of
nanomaterials were discussed, including lack of ade-
quate information regarding (i) external and internal
dose and disposition, (ii) standardized testing strate-
gies (methods, nanomaterials, characterization, and
identiﬁcation), and (iii) mechanisticuncertainties. The
WG had a sense that the current focus on mechanistic
aspects of responses to nanomaterials is not connected
to information about the relevance to human health
due to a lack of knowledge regarding exposure and
target organ doses. Critical information is needed
about exposure doses, target organs (kinetics, dispo-
sition), and uptake pathways. The lack of clarity as to
the speciﬁc challenges associated with nanomaterials,
coupled with the fact that this class covers such a
diverse range of material types, solubilities, reactivi-
ties, sizes, and other properties, presents difﬁculties in
designing suitable studies and interpreting the data
from these studies. There is also concern about the
validity of the assumption that existing endpoints are
sufﬁcientfornanoparticles(e.g.,evenafter20 yearsof
research, there is no broad agreement on a test to
predict biopersistent ﬁber-induced mesothelioma).
Indeed, recent reports have highlighted interferences
in cytotoxicity assays related to speciﬁc nanomaterial
properties (Casey et al. 2007; Ryman-Rasmussen
et al. 2007;W o ¨rle-Knirsch et al. 2006). Response
pathway analysis using gene chip technology is
promising.However,directapplicationofthegenomic
technologiestonanoparticles isnotstraightforward,as
many issues remain to be resolved, such as potential
interactions of nanoparticles with mRNA. There is
also considerable debate about relevant exposure
518 J Nanopart Res (2009) 11:513–527
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number.
Thousands of different nanomaterials are currently
under development, with many more already in use,
and it is not possible to test each individually.
Screeningassaysarethereforeneeded.Akeychallenge
is determining what should form the basis of such
assays. Focusing on physicochemical properties alone
is insufﬁcient, as these may change (e.g., agglomera-
tion, oxidation, and interaction with biomolecules)
upon contact with liquid or gaseous media and with
biological ﬂuids. Second, screening tests that focus on
toxicological mechanisms without any connection to
plausibility or real-world exposure concentrations are
oflittleuse.Thus,theworkinggroupfeltthatthesetwo
approaches should be combined with each other and
also with dosimetric information.
A lack of standardization is also a problem in many
aspects of nanomaterials research. For example,
characterization would be helped by the existence of
standard nanoparticles with full physical, chemical,
and ‘‘biological’’ characterization (the only current
standard is the United States National Institute of
Standards and Technology’s gold in three sizes which
have been characterized physically). Current charac-
terization techniques have size limitations (e.g.,
nanoparticles are at the limits of applicability for the
equations used as the basis for size characterization)
and are also affected by the states of aggregation or
agglomeration. Standards are also lacking for charac-
terizing nanoparticles in the aqueous and gaseous
media used in test systems.
Strategies for addressing risk assessment needs
As the working group was asked to address the key
research gaps affecting our ability to make realistic
assessments of the potential risks associated with
nanomaterials, our discussions focused on the types of
studies that would reduce current uncertainties the
fastest. The round-table discussions of the Working
Group resulted in the conclusion that short-term
researchshouldfocusonthefollowingthreekeyareas:
1. External exposure assessment (i.e., concentra-
tions and characteristics of nanomaterials
suspended in air or liquid),
2. Target organ dose (internal concentration, char-
acteristics), and
3. Potential screening strategies (mechanistically
relevant).
Long-term issues include the need for mechanistic
studies once the susceptible organs are identiﬁed and
addressing methodological gaps. Figure 1 summa-
rizes the Working Group’s views regarding
prioritization of future research, as described in more
detail below.
Nanomaterial characterization is of key impor-
tance and new methodologies may be needed in
support of this endeavor to characterize exposure-
associated risks. Characterization efforts underlie all
phases of the assessment and help to deﬁne, in
particular, both the external and internal doses and
exposures. This information also contributes to the
development of rapid screening tests of the intrinsic
properties of nanomaterials. In the descriptions
below, ‘‘environment’’ refers broadly to the settings
in which humans are exposed to nanomaterials, i.e.,
in the workplace or as consumers.
In addition to research on the mechanisms by
which nanomaterials may cause adverse health
effects, including to potential subpopulations with
unique sensitivity, a research area that should be
given high prioritization is that of exposure assess-
ment. This includes the characterization of how
exposure concentrations change in the environment
due to particle agglomeration/deagglomeration, solu-
bilization, and accretion of molecules in the gas or
liquid carrier. Such processes could conceivably
increase or decrease the clearance times of particles
suspended in air or water. These studies focus on the
physical behavior of particles in a carrier. However,
information is also needed about how single particles
can change in terms of size, shape, and surface
Fig. 1 Overview of research needs for human health risk
assessment of nanomaterials
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processes. Finally, there is a need to develop
standards for exposure characterization.
Since knowledge of the internal (target organ)
dose should inform mechanistic studies, priority
should also be given to ﬁlling the critical knowledge
gaps in this area. To reach target tissues, nanomate-
rials must ﬁrst penetrate one or more physiological
barriers. Therefore, more needs to be understood
about the characteristics of those barriers (such as the
respiratory tract, skin, gut, and blood-brain barrier)
with respect to penetration and subsequent distribu-
tion of nanomaterials. Second, the kinetics of
nanoparticle uptake, transport, and clearance in the
body and target organs need to be characterized. This
goal could be impeded by the limitations of current
technology, so there may be an opportunity to
develop new methodologies to achieve in situ quan-
titation and visualization of nanosized particles.
Similar to the need to understand more about the
physical changes that nanoparticles undergo in the
environment, this information is also needed with
regard to size, shape, and agglomeration changes
during transport in the body. Finally, it will be
necessary to characterize changes in the ‘‘biological
identity’’ of the nanoparticles (i.e., the biomolecule
corona), surface chemistry, and solubility of the
materials as a consequence of biodistribution.
The third high-priority research area that was
identiﬁed by the WG was the development of
screening strategies to assess the potential for health
risks related to nanomaterials exposure. Such strate-
gies should address, for one, the correlation of uptake
dose, uptake mechanism, and target organ dose with
the biomolecule corona. In addition, key aspects of
nanomaterials reactivity from a physicochemical
perspective should be addressed, including a focus
on toxicological mechanisms and dose. As both the
nanomaterials characterization efforts and mechanis-
tic studies evolve, the data can be used to develop
more meaningful screening tests.
The interplay between these three research topics
and the logical progression and information ﬂow can
be conceptualized as shown in Fig. 2. In the longer
term, again it is understood about external and
internal dose and how to characterize these; it will
be possible to identify in a meaningful way the key
pathways of response to engineered nanomaterials.
Likewise, dosimetric aspects of response can be
clariﬁed. In parallel to these investigations, it will be
important to identify disease processes (e.g., acute or
chronic inﬂammation) or vulnerabilities (e.g., senes-
cence or pregnancy) that might impact internal dose
and/or mechanisms of response to nanomaterials.
Ecological risk
State of the ﬁeld
This WG recognized that traditional risk assessment
proceduresareinadequateforpredictingtheecological
risks associated with the release of nanomaterials. The
WGdiscussedanumberofpastcasestudies,wherethe
traditional approach to risk assessment failed to reveal
unforeseen risks, including recent developments with
perﬂuorinatedsurfactants(PFOA/PFOS),whereunex-
pected fate and biological effects became evident only
after approval and inclusion of these compounds in a
variety of consumer products (e.g., Teﬂon
  coatings
for cookware and other products).
Main problem
The WG emphasized their belief that the root of the
problem lies in an inadequate application of solid
phase chemical principles (e.g., particle size, shape,
and functionality) in the risk assessment of nano-
materials. The group felt strongly that the
‘‘solubility’’ paradigm used to evaluate the risks
associated with inorganic or organic contaminants
must be replaced by a ‘‘dispersivity’’ paradigm for
evaluating the risks associated with nanomaterials.
Fig. 2 Flow chart of research topics
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of nanomaterials will exceed the capacity to conduct
adequate risk assessments using current methods and
approaches. ‘‘New generation’’ products will include
materials with targeted nanotechnology–biology
interactions, DNA-scaffolded devices, composite
materials with biological functions or photovoltaic
properties, materials for new environmental remedi-
ation technologies, self-assembling devices, and
polymer-based nanomaterials. These nanomaterials
could be available in a variety of size classes and with
different surface functionalizations, probably requir-
ing multiple risk assessments for each material.
Ways to overcome problem
The WG proposed that traditional risk assessment
processes could be augmented by having the risk
assessors play a more proactive role in evaluating all
aspects of the nanomaterial lifecycle, allowing the
assessor to better formulate the problem. Risk
assessors should be integrally involved in both the
manufacturing and material development, providing
information relevant to risk assessments to the
product developers, and involved in decisions to
utilize appropriate lower-risk materials, without
compromising the desired characteristics of the
materials. In addition, risk assessors should obtain
speciﬁc information regarding material properties for
the development of new risk models.
An improved problem formulation could come
from consideration of the chemical and physical
properties of nanomaterials; however, the WG
attendees were uncertain which properties would be
relevant or useful. Nonetheless, the WG agreed that
solid phase properties, such as particle charge,
species, or dispersion properties, or any combination
of these may be relevant to predicting environmental
fate and/or effects. Environmental fate should be
considered in terms of all exposure pathways that are
reasonable for solid phase particles.
The WG recommended that risk assessors should
utilize new assessment technologies or techniques to
assess effects. Methods are needed to assess cellular
binding and uptake. Cellular uptake processes for
nanoparticles are likely to be active (e.g., phagocy-
tosis), or at least by facilitated diffusion (e.g., protein
binding). Effects assessment methods should include
biological assays that evaluate binding to
macromolecules or organelles, phagocytic activity,
and active/passive uptake processes.
Once the nanomaterial enters the cell, toxicity can
occur via one or a combination of up to four possible
mechanisms (Fig. 3). The ﬁrst mechanism involves
the release of the chemical constituents from the
nanomaterial, which leads to toxicity through more or
less ‘‘conventional’’ processes, such as the release of
toxic anions. The second mechanism of nanomaterial
toxicity is related to the size and shape of the particle,
which produces steric hindrances or interferences
with macromolecules binding important sites. The
third mechanism of toxicity involves the surface
properties of the material, such as photochemical
properties, local electric ﬁelds, charge densities, and
electronic semi-conductance. The fourth mechanism
of toxicity is related to the capacity for nanomaterials
to act as vectors for the transport of other toxic
chemicals to sensitive tissues. Tests should be
developed to evaluate biological effects caused by
each of these mechanisms. These tests should involve
multiple species in different environmental systems,
such as aquatic and terrestrial environments. Further-
more, these tests should be cross-validated in
multiple laboratories in a coordinated international
effort.
The WG recommended that risk assessors are
ﬂexible in their implementation of new models.
Given the novelty of the nanotechnology ﬁeld, the
development of accurate risk assessment models is
expected to be an iterative process. Despite best
efforts to assess the risks associated with nanomate-
rials, previous experience indicates that we should
expect that some products will enter the environment
and cause biological effects. Therefore, risk assessors
Effects 
on
membranes
Effects on 
macro-
molecules
Effects on 
gene 
expression
Effects on 
enzyme
activity
Release of
NM constituents
Physical effects of
size and shape
Surface 
reactivity Vector for other
contaminants
Inflammatory
Response
Other 
contaminants
Light
Fig. 3 Mechanisms of toxicity of nanomaterials in organisms
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123should support programs for reconnaissance and
surveillance to detect the real world impacts of
exposure to nanomaterials. The committee recog-
nized the need for developing new tools and tests to
accomplish this task, including sensors, active/pas-
sive collection systems, monitoring systems, and
improved methods for separation and characterization
of nanomaterials. Risk assessors should use this
information, combined with information from ana-
logous studies to further reﬁne data quality objectives
and to communicate interim conclusions to a wide
group of stakeholders.
Considerations for implementation of
manufactured nanomaterial policy and
governance
State of the ﬁeld
The participants in this working group agreed to
focus discussions on policy frameworks, rather than
on the gaps of regulation which have been analyzed
elsewhere. Further, the scope of discussion was
narrowed to focus on guidance deemed helpful for
developing policies, and on the information and tools
(e.g., databases and web portals) that (i) support the
development of policies by regulators, industry, and
others, and (ii) disseminate information to the public
and others.
The WG agreed that while many different policy
frameworks for manufactured nanomaterials have
been developed globally, a signiﬁcant lag period
remains between the development of nanotechnolo-
gies and the development and implementation of new
policies. While policy initiatives range from volun-
tary measures to mandatory legislative frameworks,
the WG recognized that governments and industry
actually develop very few policies.
The document providing the foundation for the
WG’s discussions was a recent book chapter (Linkov
and Satterstrom 2008) that reviewed current nano-
material risk management frameworks. Linkov and
Satterstrom took a global survey of risk assessment
and risk management models and frameworks for
manufactured nanomaterials developed by regulatory
agencies, trade associations, not-for-proﬁt organiza-
tions, academics, and companies, and selected 13 for
in-depth review. Table 1 lists 11 documents reviewed
by the authors and, since publication of this chapter,
one additional U.S. government multi-agency frame-
work (National Nanotechnology Initiative, NNI) and
the European Union’s recently enacted Registration,
Evaluation, Authorisation, and restriction of CHem-
icals (REACH) legislation were added by the WG
participants. The documents reviewed included com-
prehensive state-of-the-science regulation framework
documents, voluntary programs, documents on the
regulation and ethics of nanomaterials, and position
statements. Linkov and Satterstrom developed a list
of criteria for comparing and contrasting these
documents (i.e., aspects of a comprehensive nano-
material risk management framework) based on work
being undertaken by Health Canada on nanotechnol-
ogy, under the categories of: (1) Science and
Research Aspects; (2) Legal and Regulatory Aspects;
(3) Social Engagement and Partnerships; and (4)
Leadership and Governance. Within each category,
Linkov and Satterstrom developed four comparison
criteria per category, and the WG also reviewed the
NNI and REACH in the same manner.
The WG agreed that developing regulatory tools is
an important gap in the knowledge necessary for
manufactured nanomaterial regulation. Further, the
WG agreed with that the starting point for develop-
ment of these tools is the set of policies and
procedures already developed by regulatory agencies
and industry for traditional industrial materials, e.g.,
surfactants and other chemical substances.
Challenges
The working group agreed that the challenges for
manufactured nanomaterial-related policies include
the need to consider the risks and beneﬁts of these
materials and their uses. However, instead of focus-
ing on estimating the exact risks and beneﬁts, the WG
noted that the efforts should be directed toward
understanding tradeoffs and ﬁnding superior risk
management alternatives.
Another challenge is the need to include an
understanding of risk perceptions, which can depend
on the applications in which the nanomaterials are
being used, and then developing appropriate risk
communication efforts. Public perception of the risks
stemming from nanotechnology is important, not
only with regard to an individual’s own exposure, but
also with regard to the individual’s perception of risk
522 J Nanopart Res (2009) 11:513–527
123T
a
b
l
e
1
E
l
e
m
e
n
t
s
o
f
n
a
n
o
m
a
t
e
r
i
a
l
r
e
g
u
l
a
t
i
o
n
f
r
a
m
e
w
o
r
k
s
d
i
s
c
u
s
s
e
d
i
n
e
a
c
h
d
o
c
u
m
e
n
t
S
c
i
e
n
c
e
a
n
d
r
e
s
e
a
r
c
h
a
s
p
e
c
t
s
L
e
g
a
l
a
n
d
r
e
g
u
l
a
t
o
r
y
a
s
p
e
c
t
s
S
o
c
i
a
l
e
n
g
a
g
e
m
e
n
t
a
n
d
p
a
r
t
n
e
r
s
h
i
p
s
L
e
a
d
e
r
s
h
i
p
a
n
d
g
o
v
e
r
n
a
n
c
e
1
2
3
4
1
2
3
4
1
2
3
4
1
2
3
4
U
S
E
P
A
2
0
0
7
j
j
j
j
j
j
j
j
j
j
j
j
j
j
j
U
S
F
D
A
2
0
0
7
j
j
j
j
j
j
j
j
D
a
v
i
e
s
2
0
0
6
j
j
j
j
j
j
j
j
j
j
j
j
j
j
E
D
-
D
u
P
o
n
t
2
0
0
7
j
j
j
j
j
j
j
j
j
j
j
j
Q
u
e
´
b
e
c
C
o
m
m
i
s
s
i
o
n
2
0
0
6
j
j
j
j
j
j
j
j
j
j
j
j
j
j
U
K
R
o
y
a
l
S
o
c
i
e
t
y
2
0
0
4
j
j
j
j
j
j
j
j
j
j
j
j
j
j
j
j
U
K
D
E
F
R
A
2
0
0
6
j
j
j
j
j
j
j
j
R
e
s
p
o
n
s
i
b
l
e
N
a
n
o
C
o
d
e
2
0
0
6
j
j
j
j
j
E
C
S
C
E
N
I
H
R
2
0
0
7
j
j
j
j
E
C
A
c
t
i
o
n
P
l
a
n
2
0
0
5
j
j
j
j
j
j
j
j
j
j
j
I
R
G
C
2
0
0
5
,
2
0
0
6
,
2
0
0
7
j
j
j
j
j
j
j
j
j
j
j
j
j
j
U
S
N
N
I
2
0
0
8
j
j
j
j
j
j
j
j
j
j
R
E
A
C
H
2
0
0
6
j
j
j
j
j
j
j
j
j
j
j
j
j
j
j
j
S
u
b
-
c
r
i
t
e
r
i
a
f
o
r
t
h
e
t
a
b
l
e
a
r
e
a
s
f
o
l
l
o
w
s
S
c
i
e
n
c
e
a
n
d
r
e
s
e
a
r
c
h
a
s
p
e
c
t
s
S
o
c
i
a
l
e
n
g
a
g
e
m
e
n
t
a
n
d
p
a
r
t
n
e
r
s
h
i
p
s
1
.
D
e
v
e
l
o
p
m
e
n
t
o
f
m
e
t
h
o
d
s
f
o
r
d
e
t
e
c
t
i
o
n
/
c
h
a
r
a
c
t
e
r
i
z
a
t
i
o
n
/
d
a
t
a
c
o
l
l
e
c
t
i
o
n
1
.
P
r
o
m
o
t
i
o
n
o
f
e
d
u
c
a
t
i
o
n
a
n
d
d
i
s
t
r
i
b
u
t
i
o
n
o
f
i
n
f
o
r
m
a
t
i
o
n
/
u
s
e
o
f
r
i
s
k
c
o
m
m
u
n
i
c
a
t
i
o
n
t
o
o
l
s
2
.
A
s
s
e
s
s
m
e
n
t
o
f
e
n
v
i
r
o
n
m
e
n
t
a
l
f
a
t
e
&
t
r
a
n
s
p
o
r
t
/
i
m
p
a
c
t
s
2
.
U
s
e
o
f
s
t
a
k
e
h
o
l
d
e
r
e
n
g
a
g
e
m
e
n
t
t
o
o
l
s
3
.
A
s
s
e
s
s
m
e
n
t
o
f
t
o
x
i
c
o
l
o
g
y
/
h
u
m
a
n
h
e
a
l
t
h
i
m
p
a
c
t
s
3
.
D
e
v
e
l
o
p
m
e
n
t
o
f
p
a
r
t
n
e
r
s
h
i
p
s
w
i
t
h
a
c
a
d
e
m
i
a
,
i
n
d
u
s
t
r
y
,
p
u
b
l
i
c
o
r
g
a
n
i
z
a
t
i
o
n
s
,
p
r
o
v
i
n
c
e
s
,
a
n
d
i
n
t
e
r
n
a
t
i
o
n
a
l
r
e
g
u
l
a
t
o
r
s
4
.
A
s
s
e
s
s
m
e
n
t
o
f
h
e
a
l
t
h
a
n
d
e
n
v
i
r
o
n
m
e
n
t
a
l
e
x
p
o
s
u
r
e
4
.
E
m
p
h
a
s
i
s
o
f
e
t
h
i
c
a
l
c
o
n
d
u
c
t
L
e
g
a
l
a
n
d
r
e
g
u
l
a
t
o
r
y
a
s
p
e
c
t
s
L
e
a
d
e
r
s
h
i
p
a
n
d
g
o
v
e
r
n
a
n
c
e
1
.
V
o
l
u
n
t
a
r
y
r
e
g
u
l
a
t
o
r
y
a
n
d
b
e
s
t
-
p
r
a
c
t
i
c
e
s
m
e
a
s
u
r
e
s
1
.
T
r
a
n
s
p
a
r
e
n
c
y
i
n
n
a
n
o
t
e
c
h
n
o
l
o
g
y
-
r
e
l
a
t
e
d
d
e
c
i
s
i
o
n
s
2
.
I
n
f
o
r
m
a
t
i
o
n
-
b
a
s
e
d
r
e
g
u
l
a
t
o
r
y
t
o
o
l
s
(
e
.
g
.
,
l
a
b
e
l
i
n
g
)
2
.
C
o
n
s
i
d
e
r
a
t
i
o
n
o
f
b
e
n
e
ﬁ
t
s
o
f
n
a
n
o
t
e
c
h
n
o
l
o
g
y
3
.
E
c
o
n
o
m
i
c
-
b
a
s
e
d
r
e
g
u
l
a
t
o
r
y
t
o
o
l
s
(
e
.
g
.
,
t
a
x
o
r
f
e
e
f
o
r
s
a
f
e
t
y
t
e
s
t
i
n
g
)
3
.
A
d
a
p
t
i
v
e
m
o
d
i
ﬁ
c
a
t
i
o
n
o
f
e
x
i
s
t
i
n
g
o
r
d
e
v
e
l
o
p
m
e
n
t
o
f
n
e
w
l
e
g
i
s
l
a
t
i
o
n
4
.
L
i
a
b
i
l
i
t
y
-
b
a
s
e
d
r
e
g
u
l
a
t
o
r
y
t
o
o
l
s
(
e
.
g
.
,
p
e
n
a
l
t
y
f
o
r
p
o
l
l
u
t
i
o
n
)
4
.
C
o
n
s
i
d
e
r
a
t
i
o
n
o
f
p
r
e
c
a
u
t
i
o
n
a
r
y
p
r
i
n
c
i
p
l
e
C
r
i
t
e
r
i
a
a
r
e
n
u
m
b
e
r
e
d
1
t
o
4
u
n
d
e
r
e
a
c
h
c
a
t
e
g
o
r
y
;
f
o
r
e
a
c
h
d
o
c
u
m
e
n
t
a
n
d
c
r
i
t
e
r
i
o
n
,
j
=
d
o
c
u
m
e
n
t
d
i
s
c
u
s
s
e
d
t
h
e
c
r
i
t
e
r
i
o
n
,
j
=
d
o
c
u
m
e
n
t
m
e
n
t
i
o
n
e
d
t
h
e
c
r
i
t
e
r
i
o
n
,
a
n
d
b
l
a
n
k
=
d
o
c
u
m
e
n
t
d
i
d
n
o
t
a
d
d
r
e
s
s
t
h
e
c
r
i
t
e
r
i
o
n
;
a
d
a
p
t
e
d
f
r
o
m
L
i
n
k
o
v
a
n
d
S
a
t
t
e
r
s
t
r
o
m
2
0
0
8
J Nanopart Res (2009) 11:513–527 523
123to others (e.g., the family of a person) and to the
environment. The WG recognized that public per-
ceptions of nanomaterial risk may differ from the
perceptions of policy makers and technical experts
(including risk assessors), and that any differences in
mental models for nanomaterial risk perceptions
between general public and technical experts should
be highlighted and used to inform communication
efforts.
Several additional challenges were noted by the
WG. For example, as with other substances in the
environment, regulators involved with the develop-
ment of nanomaterial-related policies need to
consider the differences between manufactured
nanomaterials and both engineered and non-engi-
neered anthropogenic nanomaterials, and the
associated scientiﬁc and legal challenges by separa-
ting these materials for risk assessment, risk
management, and policy purposes. Another challenge
discussed by the WG was the need to understand the
complex relationships between sources and the
related exposure pathways to many potential
receptors.
Finally, the WG noted a need for a common,
standardized taxonomy and terminology for nanom-
aterials which captures key aspects of their physical
and chemical characteristics, together with the estab-
lishment of standardized use categories.
Strategies for addressing policy needs
The WG generally agreed with the strategies noted in
the Linkov and Satterstrom (2008) book chapter.
These include:
• A ‘‘regulatory pyramid’’ (with self-regulation at
the pyramid’s base and prescriptive legislation at
the apex) is needed. However, some members of
the WG noted that the huge diversity of possible
nanomaterials makes the pyramid approach very
challenging, and that it would be impossible to
develop a ‘‘one-way-to-go’’ methodology to sup-
port the development of policies. This is
especially true in countries where more than one
regulatory agency is involved in the regulatory
process for manufactured nanomaterials.
• An adaptive management approach should be
utilized to respond to new developments and gain
additional information through policy.
• The framework should employ multiple tools at
different levels of the regulatory pyramid, with
speciﬁc tools chosen on a case-by-case basis.
• Information- or economics-based tools would
help both bottom-up (i.e., self-regulation) and
top-down approaches (i.e., prescriptive regula-
tion) for the assessment, management, and
regulation of nanomaterials.
• Multicriteria decision analysis, including stake-
holder engagement, can be used to prioritize
regulatory knowledge gaps, select speciﬁc regu-
latory tools, and also to allocate limited resources
and focus follow-up activities.
• An adaptive, tiered integration of risk manage-
ment with decision support would thus be ideal.
Further, the WG agreed that:
• A common, standardized taxonomy and termi-
nology for nanomaterials, including the capturing
of key aspects of their physical and chemical
characteristics, together with the establishment of
standardized use categories, should be the global
goal. This would facilitate the development of
information resources (e.g., publications and
other documents, and databases) that provide
easy access and sharing across countries as
regulators attempt to understand and assess the
properties of new materials compared to similar
materials. Attempts could be made to have a
leading global organization(s) for key aspects of
this effort.
• The differences between the sources and intended
uses of nanoscaled particles (naturally occurring
versus manufactured) need to be acknowledged
and considered when developing policies and
frameworks.
• Interactions and collaborations among regulators,
scientists, and other stakeholders should continue
and be further encouraged to develop coherent,
adequate policies to address such a dynamic ﬁeld.
• The ideal policy should take a holistic viewpoint,
considering the entire lifecycle of a nanomaterial,
in addition to the production, transport, and
disposal/recycling.
• The main exposure considerations for policy
development include occupational, consumer,
and general population exposures of humans,
and environmental exposures of ecological
receptors.
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123• Ecological and human health effects should be
considered for all reasonably foreseeable expo-
sures in multiple media.
• Attempts should continue to be made by both
companiesandregulatoryagenciestocommunicate
information about manufactured nanomaterials to
the public. The WG noted the efforts of the
not-for-proﬁt organization GreenFacts (www.
greenfacts.org) to provide information. See: http://
copublications.greenfacts.org/en/nanotechnologies/
index.htm
• Development of a crisis-/catastrophe plan for
manufactured nanomaterials should be considered
by both companies and regulatory agencies. The
recent case of the Magic Nano consumer products
in Germany being associated with respiratory
problems was discussed by the WG as both a
good and bad example of how such a crisis should
be addressed by material suppliers, consumer
product companies, and regulatory agencies (e.g.,
see http://www.smalltimes.com/Articles/Article_
Display.cfm?ARTICLE_ID=270664&p=109 and
http://www.bfr.bund.de/cm/279/frequently_asked_
questions_on_nanotechnology.pdf).
Conclusion
Workshop attendees shared basic agreements on
policy and risk assessment needs across countries.
Attendees identiﬁed the need for a common, stan-
dardized taxonomy and terminology for nano-
materials in which key aspects should include
nanomaterial physical and chemical characteristics,
with the view that such a system would facilitate the
development of informational resources (e.g., publi-
cations, other documents, and databases) to provide
easy access and sharing across international borders
as regulators attempt to understand and assess the
properties of these new materials. Attendees also
agreed that assessments covering the entire lifecycle
would best inform and guide risk assessment for
engineered nanomaterials and related nanotechnolo-
gies, and that consumer and occupational health
protection policies needed additional development as
well. Given the proprietary nature of these rapidly
evolving technologies, and current voluntary report-
ing requirements, a mechanism is needed for
regularly providing and updating information to
scientists and policy makers regarding the safety
proﬁles and characteristics of these current and
emerging nanomaterials. Attendees were very aware
that a serious nanomaterials-related health issue in
one nation or region of the world would greatly
promote a negative public perception of nanomate-
rials risk in every other nation or area.
Simultaneous advances in different disciplines are
necessary to advance nanomaterials risk assessment
and risk management. Risk assessment is an inter-
disciplinary ﬁeld, but progress in risk assessment has
historically occurred due to advances in individual
disciplines. For example, toxicology has been central
to human health risk assessment, and advances in
exposure assessment have been important for envi-
ronmental risk assessment and risk management.
Nanotechnology, however, ideally involves the
planned and coordinated development of knowledge
across ﬁelds, such as biology, chemistry, materials
science, and medicine.
Likewise, a risk assessment of nanomaterials and
related technologies requires a lifecycle approach,
meaning a comprehensive assessment of the impact of
nanomaterials at different stages of production, use,
anddisposal/recycling.Thecurrentstateofknowledge
makes the identiﬁcation of major risk drivers chal-
lenging. This includes understanding environmental
pathways,fateandtransportprocesses,andreasonably
foreseeable exposures. An integrated, holistic
approach is needed to consider an individual’s total
exposure from relevant environments expressed in
different units across receptor groups. This would lead
to risk characterizations that are systematic and more
inclusive, accommodatingnon-traditionalinformation
sources, measures, and endpoints.
The attendees agreed that while existing chemical
risk assessment and risk management frameworks
may provide a starting point, the unique properties of
nanomaterials adds a signiﬁcant level of complexity
to this process. The goals of this workshop included
the identiﬁcation of strategies and tools that could
currently be implemented to reduce technical uncer-
tainty and prioritize research to address the immediate
needs of the regulatory and risk assessment commu-
nities. Such tools include advanced risk assessment,
comprehensive environmental assessment, risk char-
acterization methods, decision analysis techniques,
and other approaches to help focus research and
inform policymakers beneﬁting the world at large.
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